Approval · Notice of Compliance 38438 · 2026
SANDOZ CANDESARTAN PLUS: Notice of Compliance 38438
Issued October 8, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38438
- Date
- October 8, 2026
- Company
- Sandoz Canada Inc.Saint-Hubert, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to package labels
- Canadian reference product
- ATACAND PLUS (Astrazeneca Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SANDOZ CANDESARTAN PLUS | Not yet assigned | — |
Medicinal ingredients
- HYDROCHLOROTHIAZIDE 12.5 MG per TAB
- CANDESARTAN CILEXETIL 16 MG per TAB
- CANDESARTAN CILEXETIL 32 MG per TAB
- HYDROCHLOROTHIAZIDE 25 MG per TAB